DHRHealth Institute for Research and Development
News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

D5290C00004 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

Study Status:


Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

This study aims to assess the efficacy of MEDI8897 when administered as a single fixed IM dose to infants ≥ 35 weeks 0 days GA and entering their first RSV season, in reducing medically attended LRTI due to RT-PCRconfirmed RSV, compared to placebo.


Principal Investigator
Dynio Honrubia, MD
Type of Trial
© 2023 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram